Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 7:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Cardiovascular Diseases
Interventions
Empagliflozin, Placebos
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Effect of C-peptide on Hypoglycemic Counterregulation

NCT06470295
Conditions
Hypoglycemia, Type 1 Diabetes
Interventions
Saline, C-peptide
Other · Biological
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 40 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)

NCT03608163
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
Interventions
Naloxone, Diazoxide, Placebo (for Naloxone), Placebo (for Diazoxide)
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
The Bronx, New York
Completed No phase listed Observational Accepts healthy volunteers

Relationship Between HbA1c and Chronic Glycemia in Patients With Cirrhosis

NCT02389127
Conditions
Cirrhosis, Diabetes Mellitus, Type 2
Interventions
Continuous glucose monitor (Dexcom, San Diego, CA)
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Completed Not applicable Interventional Accepts healthy volunteers

The Functional Neuroanatomy of the Human Physiological Stress Response

NCT03867344
Conditions
Hypoglycemia, Physiological Stress
Interventions
Hypoglycemic Hyperinsulinemic Clamp, Normoglycemic Hyperinsulinemic Clamp
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, Insulin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
5
States / cities
Chula Vista, California • Butte, Montana • Portland, Oregon + 2 more
Conditions
Brain Edema, Stroke, Acute
Interventions
BIIB093, Placebo
Drug
Lead sponsor
Remedy Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
74
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 59 more
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function
Drug · Device · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Terminated Phase 4 Interventional Results available

Fatty Liver Study in Patients With Type II Diabetes

NCT02365233
Conditions
Type II Diabetes, Nonalcoholic Fatty Liver
Interventions
DPP4 inhibitor, Pioglitazone, Lantus insulin
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Type 1 Diabetes Mellitus
Interventions
Predictive Low Glucose Suspend Algorithm ON, Predictive Low Glucose Suspend Algorithm OFF
Device
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 46 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Comparing Facial Aging Between Identical Twins With 3D Imaging

NCT07760532
Conditions
Facial Skin Aging, Facial Volume Loss, Wrinkle Appearance
Interventions
GLP-1 Receptor Agonists
Drug
Lead sponsor
Ponsky Facial Aesthetics And Plastic Surgery, Llc
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Beachwood, Ohio
Conditions
Kidney Disease, Chronic, Diabetes
Interventions
SGLT2 inhibitor
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
714,582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Titusville, New Jersey
Conditions
Hypoglycemic Events, Hyperglycemic Therapy
Interventions
EndoTool, glucose management team, standard of care glucose management
Diagnostic Test · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Metformin XR, dapagliflozin matching Placebo, metformin HCl Modified Release matching Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
64
States / cities
Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
39
States / cities
Vestavia Hills, Alabama • Tucson, Arizona • Carlisle, Arkansas + 32 more
Conditions
Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)
Interventions
exenatide, Other antidiabetic therapies, No diabetes therapy
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
363,766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Waltham, Massachusetts
Conditions
Type 1 Diabetes Mellitus With Hypoglycemia
Interventions
Glucagon, Insulin
Drug
Lead sponsor
Abvance Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Interventions
Metformin, Sulfonylurea, DPP-4 inhibitor, SGLT2 inhibitor, GLP1 receptor agonist
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
4,888 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Nashville, Tennessee
Enrolling by invitation Early Phase 1 Interventional

Truway Diagnostic Tools in Primary Care

NCT07209527
Conditions
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute, Hyperlipidemia, Chronic Kidney Disease (CKD), Stages 3-4 Exercise Tolerance / Functional Capacity Vascular Health / Arterial Stiffness Fatigue in CKD, Peripheral Artery Disease, Metabolic Syndrome, Prediabetes
Interventions
Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2

NCT00574639
Conditions
Type 1 Diabetes
Interventions
Alprazolam, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Glucagon Administration on Energy Expenditure

NCT02237053
Conditions
Hyperglucagonemia, Obesity
Interventions
Glucagon, Octreotide, Placebo, Insulin
Drug · Behavioral
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Type 2 Diabetes, Hypogonadism
Interventions
Androgel (testosterone gel)
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
70
States / cities
Birmingham, Alabama • Calera, Alabama • Mobile, Alabama + 54 more
Conditions
Type 2 Diabetes Mellitus
Interventions
Pioglitazone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Houston, Texas